CSIMarket
 


Regeneron Pharmaceuticals Inc   (REGN)
Other Ticker:  
 
 

REGN's Net Cash Flow Growth by Quarter and Year

Regeneron Pharmaceuticals Inc 's Net Cash Flow results by quarter and year




REGN Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 577.60 -385.40 -546.80 620.70
III Quarter September 210.50 96.20 1,360.20 -418.10
II Quarter June -1,979.10 49.40 634.30 -216.00
I Quarter March 809.40 461.10 -756.90 590.40
FY   -381.60 221.30 690.80 577.00



REGN Net Cash Flow fourth quarter 2023 Y/Y Growth Comment
Regeneron Pharmaceuticals Inc in the fourth quarter 2023 achieved Net Cash Flow of $ 577.60 millions compare to net cash outflow recorded in same quarter a year ago.

According to the results reported in the fourth quarter 2023, Regeneron Pharmaceuticals Inc achieved the best Net Cash Flow growth in Major Pharmaceutical Preparations industry. While Regeneron Pharmaceuticals Inc ' s Net Cash Flow no change of % ranks overall at the positon no. in the fourth quarter 2023.




REGN Net Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - 313.52 %
III Quarter September 118.81 % -92.93 % - -
II Quarter June - -92.21 % - -
I Quarter March 75.54 % - - 145.18 %
FY   - -67.96 % 19.72 % 284.41 %

Financial Statements
Regeneron Pharmaceuticals Inc 's fourth quarter 2023 Net Cash Flow $ 577.60 millions REGN's Income Statement
Regeneron Pharmaceuticals Inc 's fourth quarter 2022 Net Cash Flow $ -385.40 millions Quarterly REGN's Income Statement
New: More REGN's historic Net Cash Flow Growth >>


REGN Net Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 174.39 % - - -
III Quarter September - 94.74 % 114.44 % -
II Quarter June - -89.29 % - -
I Quarter March - - - 293.34 %
FY (Year on Year)   - -67.96 % 19.72 % 284.41 %




Net Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Regeneron Pharmaceuticals Inc 's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
900.38 % 128.43 % -95.34 %
(Mar 31 2018)  


REGN's IV. Quarter Q/Q Net Cash Flow Comment
Regeneron Pharmaceuticals Inc achieved in the IV. Quarter 2023 above company average sequential Net Cash Flow doubling of 174.39%, to $ 577.60 millions, from $210.50 millions in the third quarter.
Major Pharmaceutical Preparations company is undergoing a remarkable growth, with reporting higher then normal increase, and also improving pace.

Within Major Pharmaceutical Preparations industry only one company achieved higher sequential Net Cash Flow growth. While Regeneron Pharmaceuticals Inc 's Net Cash Flow growth quarter on quarter, overall rank is 49.


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #2
Overall #49
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #2
Healthcare Sector #2
Overall #49
Net Cash Flow Q/Q Growth Statistics
High Average Low
900.38 % 128.43 % -95.34 %
(Mar 31 2018)  


REGN's IV. Quarter Q/Q Net Cash Flow Comment
Regeneron Pharmaceuticals Inc achieved in the IV. Quarter 2023 above company average sequential Net Cash Flow doubling of 174.39%, to $ 577.60 millions, from $210.50 millions in the third quarter.
Regeneron Pharmaceuticals Inc is undergoing a remarkable growth, not only reporting better then regular growth, but also accelerating pace.

Within Major Pharmaceutical Preparations industry only one company achieved higher sequential Net Cash Flow growth. While Regeneron Pharmaceuticals Inc 's Net Cash Flow growth quarter on quarter, overall rank is 49.


Regeneron Pharmaceuticals Inc 's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Net Cash Flow 12 Months Ending $ -381.60 $ -1,344.60 $ -1,458.90 $ 569.60 $ 221.30
Y / Y Net Cash Flow Growth (TTM) - - - -70.16 % -67.96 %
Year on Year Net Cash Flow Growth Overall Ranking # 74 # 421 # 20 # 48 # 181
Seqeuential Net Cash Flow Change (TTM) - - - 157.39 % 269.45 %
Seq. Net Cash Flow Growth (TTM) Overall Ranking # 29 # 419 # 174 # 170 # 297




Cumulative Net Cash Flow growth Comment
Regeneron Pharmaceuticals Inc realized trailing twelve months net cash outflow of $ -382 millions, in the Dec 31 2023, compare to Net Cash Flow of $ 221 millions a year ago.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Total ranking has impoved so far to 74, from total ranking in previous quarter at 421.

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
3208.5 %
125.82 %
-2344.74 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 3
Overall # 74

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
3208.5 %
125.82 %
-2344.74 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 0
Sector # 1
S&P 500 # 29
Cumulative Net Cash Flow growth Comment
Regeneron Pharmaceuticals Inc realized trailing twelve months net cash outflow of $ -382 millions, in the Dec 31 2023, compare to Net Cash Flow of $ 221 millions a year ago.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Net Cash Flow growth. While Total ranking has impoved so far to 74, from total ranking in previous quarter at 421.

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
3208.5 %
125.82 %
-2344.74 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 3
Overall # 74

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
3208.5 %
125.82 %
-2344.74 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 0
Sector # 1
S&P 500 # 29




Other Net Cash Flow Growth
Major Pharmaceutical Preparations Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
REGN's Net Cash Flow Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for REGN's Competitors
Net Cash Flow Growth for Regeneron Pharmaceuticals Inc 's Suppliers
Net Cash Flow Growth for REGN's Customers

You may also want to know
REGN's Annual Growth Rates REGN's Profitability Ratios REGN's Asset Turnover Ratio REGN's Dividend Growth
REGN's Roe REGN's Valuation Ratios REGN's Financial Strength Ratios REGN's Dividend Payout Ratio
REGN's Roa REGN's Inventory Turnover Ratio REGN's Growth Rates REGN's Dividend Comparisons



Companies with similar Net Cash Flow doubling for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Dec 31 2023
Astrazeneca Plc-5.29%$ -5.287 millions
Lipocine Inc -6.98%$ -6.984 millions
Caredx Inc -14.62%$ -14.617 millions
Sophia Genetics Sa-16.41%$ -16.406 millions
Xencor Inc-17.78%$ -17.780 millions
Kronos Bio Inc -20.78%$ -20.784 millions
Earth Science Tech Inc -21.38%$ -21.381 millions
Hookipa Pharma inc -22.19%$ -22.193 millions
Anaptysbio Inc -24.22%$ -24.222 millions
Koru Medical Systems Inc-26.57%$ -26.570 millions
Abbott Laboratories-35.07%$ -35.069 millions
Lantheus Holdings Inc -37.16%$ -37.161 millions
Alcon inc -37.78%$ -37.778 millions
Inflarx N v -38.04%$ -38.037 millions
Novartis Ag-39.41%$ -39.413 millions
Argenx se-40.00%$ -40.005 millions
Gh Research Plc-40.04%$ -40.040 millions
Bright Minds Biosciences Inc -41.15%$ -41.154 millions
Enzon Pharmaceuticals inc -42.33%$ -42.332 millions
Myriad Genetics Inc -44.65%$ -44.653 millions
Elutia inc -46.46%$ -46.456 millions
Gilead Sciences Inc -46.70%$ -46.704 millions
Koninklijke Philips Nv-49.11%$ -49.110 millions
Avidity Biosciences Inc -49.45%$ -49.449 millions
Proqr Therapeutics N v -49.46%$ -49.460 millions
Protalix Biotherapeutics inc -49.52%$ -49.523 millions
Xeris Biopharma Holdings Inc -49.99%$ -49.994 millions
Altair International Corp -52.34%$ -52.344 millions
Macrogenics Inc -55.57%$ -55.574 millions
Atricure Inc -59.98%$ -59.983 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com